
Dr. Ryo Takeuchi, Sr. Director, Genome Editing at Excision, will present on leveraging EBT-101 preclinical and clinical insights for new in vivo multiplex editing programs.
Learn more: loom.ly/1IfiuqE

English
Excision BioTherapeutics
214 posts

@ExcisionBio
Developing CRISPR-based therapies intended to cure viral infectious diseases.






































